

1 **Morbidity associated with *Schistosoma mansoni* infection in north-eastern**
2 **Democratic Republic of the Congo**

3 Maurice M Nigo^{1,4,8}, Peter Odermatt^{3,5}, David Wully Nigo^{6,8}, Georgette B. Salieb-Beugelaar¹,
4 Manuel Battegay^{3,7}, Patrick R Hunziker^{1, 2, 3 *}

5
6 **1** Nanomedicine Translation Group, Medical Intensive Care Clinic, University Hospital Basel
7 University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland; **2** CLINAM - European
8 Foundation for Clinical Nanomedicine, Alemannengasse 12, P.O. Box, CH-4016 Basel,
9 Switzerland; **3** University of Basel, Petersplatz 1, Basel, Switzerland; **4** Institut Supérieur des
10 Techniques Médicales (ISTM) Nyankunde, B.P. 55 Bunia, Democratic Republic of Congo **5** Swiss
11 Tropical and Public Health Institute, Socinstrasse 57, P.O. Box, CH-4002 Basel, Switzerland; **6**
12 Centre Hospitalier, Ingbokolo Town, Democratic Republic of Congo; **7** Department of Infectiology
13 & Hospital Hygiene, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. **8**
14 Circonflex Foundation, Bunia, DR Congo

15

16 **Short title:** Schistosomiasis morbidity burden in Ituri province in north-eastern Congo

17 * corresponding author: patrick.hunziker@usb.ch

18

19 **Abstract**

20 **Background**

21 Controlling morbidity is the main target of schistosomiasis control. Yet only rarely do we assess
22 morbidity linked to *Schistosoma* sp. infection. In the Democratic Republic of Congo (DRC), and
23 particularly in the north-eastern Ituri province, morbidity associated with *Schistosoma mansoni*
24 infection is unknown. For this reason, we aimed to assess intestinal and hepatosplenic morbidity
25 associated with *S. mansoni* infection in Ituri province.

26 **Methods / Principal Findings**

27 In 2017, we conducted a cross-sectional study in 13 villages in Ituri province, DRC. *S. mansoni*
28 infection was assessed with a Kato-Katz stool test (2 smears) and a point-of-care circulating
29 cathodic antigen (POC-CCA) test in urine. A questionnaire was used to obtain demographic data
30 and information about experienced intestinal morbidity. Each participant underwent an abdominal
31 ultrasonography examination to diagnose hepatosplenic morbidity. Of the 586 study participants,
32 76.6% tested positive for *S. mansoni*. Intestinal morbidity, such as abdominal pain (52.7%),
33 diarrhoea (23.4%) and blood in the stool (21.5%) in the previous two weeks, was very frequent.
34 Hepatosplenic morbidity was demonstrated by abnormal liver parenchyma patterns (42.8%),
35 hepatomegaly (26.5%), and splenomegaly (25.3%). Liver pathology (adjusted odds ratio [aOR]
36 1.20, 95% confidence interval [CI] 1.06–1.37, $P=0.005$) was positively and significantly associated
37 with *S. mansoni* infection. Hepatomegaly (aOR 1.52, 95% confidence interval [CI] 0.99–2.32,
38 $P=0.053$) and splenomegaly (aOR 1.12, 95% CI 0.73–1.72, $P=0.619$) were positively but not
39 significantly associated with *S. mansoni* infection at the individual level. At the village level, *S.*
40 *mansoni* prevalence was positively associated with the prevalence of hepatomegaly and

41 splenomegaly. Higher *S. mansoni* infection intensities were associated with diarrhoea, blood in the
42 stool, hepatomegaly, splenomegaly and with liver parenchyma, pathology patterns C, D, E and F.
43 Four study participants were diagnosed with ascites and five reported hematemesis.

44 **Conclusions/Significance:** Our study documents a high burden of intestinal and hepatosplenic
45 morbidity associated with *S. mansoni* infection status in Ituri province. The results call for targeted
46 interventions to address both *S. mansoni* infection and related morbidity.

47 **Keywords:** *Schistosoma mansoni*; Ituri province; Democratic Republic of Congo; infection
48 prevalence; infection intensity; hepatosplenic morbidity

49

50 **Author Summary**

51 Schistosomiasis caused by *Schistosoma mansoni* is of great public health importance in sub-
52 Saharan Africa. The World Health Organization (WHO) recommends that control efforts aim to
53 reduce morbidity through large scale intervention programmes. However, intestinal and liver
54 morbidity is rarely assessed in such control programmes. Hence, little is known about (i) the
55 magnitude of the intestinal and liver morbidity burden in each community, or about (ii) the
56 morbidity associated with *S. mansoni* infection, specifically. We conducted a (cross-sectional)
57 study in which we assessed intestinal morbidity by questionnaire and liver morbidity by abdominal
58 ultrasonography. Further, we determined the infection status of the study participants using
59 standard diagnostic procedures (Kato-Katz technique and point-of-care cathodic circulating *S.*
60 *mansoni* antigen [POC-CCA] test in urine). Among 586 study participants, six years and older,
61 from 13 villages in Ituri province, DRC, we observed a high degree of intestinal (e.g. 23.4% with
62 diarrhoea, 21.5% with blood in stool) and hepatosplenic morbidity (e.g. 42.8% with abnormal liver
63 patterns C, D, E, and F, 26.5% with enlarged liver, 25.3% with enlarged spleen). *S. mansoni*
64 infection was associated with liver and spleen enlargement. Likewise, *S. mansoni* infection
65 intensity was linked to diarrhoea, to liver and spleen enlargement and to pathological changes in
66 the liver parenchyma. At village level, we observed that the prevalence of enlarged liver and spleen
67 among patients increased with the prevalence of *S. mansoni* infection. We conclude that the
68 population of Ituri province carries an alarming burden of intestinal, liver and spleen morbidity
69 associated with *S. mansoni* infection. Therefore, a comprehensive control programme to address
70 this infection and disease burden is urgently required.

71

72 **Introduction**

73 Schistosomiasis, a chronic helminth infection is caused by trematodes of the genus *Schistosoma*
74 *and* belongs to the so-called neglected tropical diseases. It continues to be a major global cause of
75 morbidity and mortality [1].

76 Depending on the species, it may be of genitourinary (*Schistosoma haematobium*) or of intestinal
77 (*Schistosoma mansoni*, *S. japonicum*, *S. mekongi*, *S. intercalatum*, and *S. guineensis*) form. The
78 basis of the disease is the host's cell-mediated granulomatous immune response to the soluble
79 antigens of the parasite eggs trapped in the tissues [2, 3]. In the intestinal form the adult worm
80 dwell in the portal vein and mesenteric veinlets that drain the intestines and where the female
81 deposits the eggs during her daily migration. Chronic and heavy infections are frequently
82 associated with hepatosplenic and intestinal disease characterized by liver and spleen enlargements
83 and intestine damage. In the liver, the resulting scars may disrupt liver function and obstruct the
84 portal veins, leading to periportal fibrosis (PPF), portal hypertension, subsequently to oesophageal
85 varices and then to hematemesis and melena, and ultimately ascites, the main direct causes of death
86 due to *S. mansoni* infection [4, 5]. In the intestines, inflammation may induce diarrhoea, whereas
87 granulomas may cause polyposis with ulcers and recurrent bleeding. The resulting intestinal
88 clinical manifestations may include abdominal pain, diarrhoea, and the presence of blood in the
89 stool [2, 6]. Chronic schistosomiasis can also lead to anaemia, stunted growth and impairment of
90 cognitive development [7, 8]. Many infected people, even those with considerable infection
91 intensity, may remain asymptomatic for a long period or experience only non-specific symptoms,
92 such as nausea, headaches, fever, fatigue and abdominal pain [9].

93 Preventive chemotherapy (PCT) mass drug administration is the WHO recommended strategy for
94 both the reduction of morbidity and the control of schistosomiasis in endemic settings [10].
95 However, for several reasons, this recommendation is poorly implemented in many countries,
96 partly because of lack of commitment, funding and/or political instabilities and security issues.

97 In the Democratic Republic of Congo (DRC), the full extent of schistosomiasis morbidity burden
98 remains unknown and most of the relevant information about the disease date back for more than
99 twenty years [11, 12]. The existing publications report on *Schistosoma* infection. The few reports
100 related to morbidity mainly concern the province of Maniema in central-eastern region of the
101 country [13, 14]. For the Ituri province, morbidity due *S. mansoni* infection was mentioned in
102 colonial times [15]. Since then, only these data and those of 1970s and 1980s are summarized in
103 available reviews. On one hand, Madinga et al. [12] reported that *S. mansoni* endemic areas were
104 described in Ituri before 1954. The main foci being lying on the left bank of Lake Albert, with
105 prevalence rates ranging from 11.0% to 64.9%. Gillet and Wolfs, on the other hand, reported that
106 there were not local cases in the high hill region, and that prevalence ranged from 2.3% in Aru in
107 the north to 93.7% in a fishing village on the shore of Lake Albert [15]. Both these reviews did not
108 mention the existence of *S. haematobium* and *S. intercalatum* infections in the Ituri province [12,
109 16]. By investigating the prevalence, intensity, and the relative morbidity of *S. mansoni* infection
110 among Ugandan and Zairian school children aged 5 to 20 years in Aru region, Müller et al. found
111 that prevalence was low to moderately high. About 8.0% of children had heavy infection. Among
112 children, 15.6 to 38.0% had hepatomegaly, while 22.0 to 59.2% were diagnosed with
113 splenomegaly. However, they found that association of organomegaly with *S. mansoni* infection
114 was not significant [17].

115 To the best of our knowledge, no recent study has been undertaken since then until the national
116 survey conducted in between 2013 and 2015. Results of this survey have not yet been published.
117 However, several studies conducted in neighbouring Uganda show high infection and morbidity
118 and considerable mortality linked to *S. mansoni* infection [3, 5, 18]. The aim of the present study
119 was to assess the morbidity associated with *S. mansoni* infection in Ituri province.

120

121 **Materials and Methods**

122 **Ethics statement**

123 This study was approved by the Swiss Ethical Commission (Ref. No. UBE-15/78) and by the
124 University of Kisangani's Research Ethical Commission, (Ref No: CER/003/GEAK/2016).
125 Research authorization was granted by the Nyankunde Higher Institute of Medical Techniques (Ref
126 No 70/ISTM-N/SGAC/2017), Bunia, DRC. Permission for field work was obtained from the Ituri
127 Provincial Health Division (Ref. 054/433/DPS/IT/06/2016 and Ref. 054/472/DPS/IT/06/2017) and
128 from all relevant health districts. Prior to enrolment, the study objectives and procedures were
129 explained to each participant in the local language and all their questions were answered. Written
130 informed consent was obtained from all study participants aged 15 years and older. Parents or legal
131 guardians signed consent forms for participants aged <14 years. Participants diagnosed with *S.*
132 *mansoni* were treated with praziquantel (40mg/kg) [19]. All participants received Mebendazole
133 (500mg, single dose, Vermox®) for general deworming, in accordance with the DRC national
134 deworming guidelines.

135 **Study area**

136 This study was conducted in the Ituri province, north-eastern DRC (geographical coordinates:
137 1.30°–3.60° latitude and 27.00°–31.40° longitude). Ituri province has an area of about 65,658 km²
138 and is home to 5.2 million inhabitants from five different ethnic groups (Nilo-Hamites, Bantu,
139 Nilotic, Sudanese, and Pygmy). It is divided into 5 territories (counties) and 36 health districts, and
140 is bordered by Lake Albert in the east, while several streams and rivers irrigate the province. These
141 waterways are suitable environments for schistosome's intermediate host snails. This study
142 involved specifically six health districts that were purposively selected because of their high
143 prevalence of *S. mansoni* infection: Angumu, Bunia, Lolwa, Mandima, Nia-Nia, and Tchomia.
144 From these health district, a total 13 villages were purposively selected. Bunia health district being
145 the biggest with a population of more than 500,000 inhabitants, had the lion's share with 5 selected
146 villages: Lumumba, Simbilyabo, Kindia, Gupe, Sukisa, and Ngezi. For the other health districts, 2
147 villages from Angumu, namely Gupe and Ndaru-Muswa. 2 from Lolwa: Mambau and Pekele, 2
148 from Nia-Nia: Bankoko and Mangenengene, 1 from Mandima: Mandima, and 1 from Tchomia:
149 Kadjugi. The presence of *Schistosoma mansoni* has been widely documented in the province in
150 colonial times. The transmission was considered to occur mainly along Lake Albert's shores [15].
151 Both the review of the available literature and the consultation of the provincial NTDs control
152 program did not mention the presence of *S. haematobium* in Ituri province and in our prior work
153 in the area (MNN, unpublished information), we did not find *S. haematobium*. *Schistosoma*
154 *intercalatum* is mentioned by few authors. For these reasons, we only concentrated our efforts to
155 study morbidity related to intestinal schistosomiasis (*S. mansoni* and *S. intercalatum*) in the Ituri
156 province [12, 15, 16]. Only a small proportion of the population residing in Bunia city has access
157 to an adequate water supply. Most of the population uses natural water bodies (springs, ponds,
158 streams) as its main water source.

159 **Study design and population**

160 We conducted a cross-sectional, household-based, in-depth study in the 13 purposely selected
161 villages across six health districts in Ituri province. Two stage sampling procedures were to select
162 both households and individuals for the study. At least 10 households were randomly selected in
163 each village and all individuals aged 6 years and older, women and men, present on the day of the
164 survey were enrolled. Household's visitors, as well as mentally and terminally ill persons were
165 excluded.

166 The study incorporated household and individual questionnaires; anthropometric assessments; and
167 parasitological, clinical, and abdominal ultrasonographic examinations.

168 **Procedures**

169 Individual questionnaires

170 All participants were invited to participate in an interview, conducted using a pre-tested
171 questionnaire. This individual questionnaire focused on demographic, anthropometric,
172 occupational, educational, and religious characteristics, as well as on knowledge, attitude and
173 practices related to *S. mansoni* infection and disease. The questionnaire also helped to assess for
174 signs and symptoms related to schistosomiasis, such as diarrhoea or blood in the stool in the
175 previous two weeks, and a history of hematemesis at any time, at least once.

176 Anthropometric measurements

177 Participants' height and weight were measured by a Seca analog bathroom scale and height rod
178 and reported to the nearest half kilogram (0.5 kg) and half centimetre (0.5 cm), respectively.

179 Participants' body mass index (BMI) was also calculated (weight in kilograms divided by the
180 square of the person's height in metres, kg/m²).

181 Parasitological examination

182 Participants were asked to provide one faecal sample (approx. 5 grams of morning stool) in a
183 labelled plastic container for testing with the Kato-Katz technique [20]. From each stool specimen,
184 two thick smears of 41.7 mg [20] were prepared and examined by experienced technicians. To
185 allow for hookworm assessment, all smears were examined by microscope within one hour after
186 preparation. All slides were examined for *S. mansoni* within 24 hours after stool collection. One
187 third of the prepared smears were checked by the principal investigator. All helminth eggs were
188 counted and recorded for each species separately. The intensity of the helminth infection was
189 calculated by multiplying the mean number of eggs found on the two slides by 24. The result was
190 expressed as eggs per gram (EPG) of stool [8].

191 Participants were also asked to provide a urine sample (approx. 60 ml) in a pre-labelled, wide-
192 mouth, plastic container, for the detection of circulating *S. mansoni* antigens using a point-of-care
193 circulating cathodic antigen (POC-CCA) test. Both the stool and urine examinations were
194 performed at the relevant village health centre facility.

195 The POC-CCA tests were performed according to the manufacturer's guidelines (Rapid Medical
196 Diagnostics, Pretoria, South Africa). Urine was examined on the day of collection. In cases where
197 the test was postponed until the next day, urine samples were kept in a solar fridge, at 2–8⁰C (Steca,
198 Germany). Test results were deemed negative if the POC-CCA band did not appear within 20
199 minutes. Trace, weak, medium, and strong coloured CCA bands were recorded as positive results.
200 Questionable results were discussed among at least two technicians and the principal investigator.

201 Clinical examination

202 All participants underwent clinical and abdominal ultrasonography examinations. Clinical
203 examinations consisted of physical examinations performed by an experienced physician and
204 assisted by an experienced nurse.

205 Abdominal ultrasound examination

206 An abdominal ultrasound was performed for each participant, according to Niamey protocol [21]
207 and using a 2.0 MHz convex transducer U-Lite Sonoscanner Ultraportable HD Ultrasound Unit
208 (U-Lite, Sonoscanner, 6, Rue André Voguet, Paris, France). A portable generator (MK, China) and
209 solar powered batteries (for remote villages) were used as electricity sources.

210 Participants were examined in a supine position. The size of the left lobe from the cranial to the
211 caudal was measured at about 2 cm in the left parasternal line (PSL), from the xyphoid. The height
212 and the width of the spleen were also measured. The length and the width of the spleen were
213 measured, and its texture evaluated. All the measures were taken in centimetres and performed
214 using the callipers on the screen the device according the manufacturer recommendations. Organs'
215 measures were then adjusted to the height of the individual and compared with those of the
216 Senegalese healthy control individuals [22]. The organs were considered enlarged when the size
217 values exceeded two standard deviations (2 SD) from the mean adjusted values of the reference
218 control individuals. Liver parenchyma patterns (Figure S1) were assessed following the
219 WHO/TDR guidelines as grade A: normal, and B: incipient, C: probable, D, E, and F as frank
220 periportal fibrosis [21]. The inner portal vein diameter was measured. The inner gall bladder length
221 and width, and the wall thickness were also measured.

222 **Data management and analysis**

223 Data was entered in Excel and cross-checked against the data sheet. STATA, version 14.2 software
224 (Stata Corp, College Station, USA) was used for data management and analysis. Only participants
225 with a complete dataset were retained in the analysis (Figure 1). Seven age groups were established:
226 (i) 6–9 years, (ii) 10–14 years, (iii) 15–19 years, (iv) 20–29 years, (v) 30–39 years, (vi) 40–49
227 years, and ≥ 50 years. Body mass index (BMI) was calculated and four categories were set:
228 underweight (< 18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), and
229 obese (≥ 30 kg/m²). Infection prevalence was expressed as the number of *S. mansoni*-positive
230 individuals divided by the total number of participants examined. Infection intensity was estimated
231 based on helminth egg counts per gram of stool (EPG) when examined with the Kato-Katz
232 technique [20]. *S. mansoni* infection intensities were classified as light (1–99 EPG), moderate
233 (100–399 EPG), and heavy (≥ 400 EPG) [8].

234 Arithmetic mean infection intensity was calculated. Categorical variables were presented as
235 frequencies and percentages. Pearson's chi-square (χ^2) test was used to compare frequency
236 distributions. A univariate logistic regression analysis was carried out to identify associations
237 between *S. mansoni* infection status (outcome) and morbidity indicators (predictors) and/or
238 demographic factors (age, gender). Predictors with a significance level of 20% or less, and age and
239 gender variables were included in the multivariable logistic regression models. Odds ratios (OR),
240 adjusted OR (aOR), and corresponding 95% confidence intervals (95% CI) were calculated. *P*-
241 values < 0.05 were considered statistically significant. The diagnostic approach combining results
242 of the Kato-Katz technique and those of POC-CCA was used in this study. As a comparison, the
243 same analysis was repeated for the diagnosis with the Kato-Katz technique and the POC-CCA
244 alone.

245 Ultrasonographic measures of organs were defined as enlarged for left liver lobe and spleen length
246 exceeding 2 SD above the normal reference value. Portal vein diameter was considered as enlarged
247 if exceeding 2 SD above the normal reference value. Liver patterns A and B were considered
248 normal, patterns C and D, mild PPF, while patterns E, and F were recorded as severe PPF.

249 **RESULTS**

250 **Study population**

251 Data were collected between June and September 2017. We enrolled participants from 13
252 purposely selected villages across six health districts with an anticipated high prevalence of *S.*
253 *mansoni* infection. Of the 949 individuals enrolled (Figure 1), 586 completed all study procedures
254 and had a complete dataset, that is, one stool sample examined with two Kato-Katz smears, a urine
255 sample tested with POC-CCA, two completed questionnaires, and a clinical and abdominal
256 ultrasound examination.

257 Among those with a complete dataset, 342 (58.4%) were females, 330 (56.3%) were under 20 years
258 of age, and 268 (45.7%) were underweight (Table 1). The prevalence of *S. mansoni* was 59.2%,
259 65.7%, and 76.6% according to Kato-Katz, POC-CCA and combined test results, respectively.
260 Thirty-seven percent, 15.2% and 7.2% of the population had light-, moderate- and heavy-intensity
261 infections, respectively. Infection with soil transmitted helminths (STH) was not common among
262 participants, with only eight participants diagnosed with an STH infection. In contrast, intestinal
263 symptoms were very common, with 52.7%, 23.4% and 21.5%, reporting abdominal pain,
264 diarrhoea, and blood in the stool within the two weeks preceding the survey, respectively. Five
265 participants (0.9%) had experienced hematemesis at least once in his/her life. Abdominal
266 ultrasound examinations revealed that 26.5% of participants had hepatomegaly, 25.3%
267 splenomegaly, and 42.8% had liver pathology; 36.4% had mild PPF (patterns C and D), 6.4% had
268 severe PPF (patterns E and F) and 1.2% presented other liver patterns not linked with
269 schistosomiasis (patterns X, Y, and Z), and 0.7% had ascites. Only 56.0% of the participants had a

270 normal liver parenchyma (patterns A and B). More details on liver parenchyma patterns are shown
 271 in Table S7 and S8.

272 **Figure 1: Flowchart of participant inclusion/exclusion in the 2017 Ituri morbidity study**
 273 **across 13 villages.**

274 **Table 1: Study sample characteristics in the 2017 Ituri infection and morbidity study.** Study
 275 conducted in 13 purposively selected villages in Ituri province (n=586).

277 Characteristics	278 N	278 %
279 Gender		
280 Females	342	58.4
281 Males	244	41.6
282 Age categories (years)		
283 6 – 9	123	21.0
284 10 – 14	140	23.9
285 15 – 19	67	11.4
286 20 – 29	77	13.1
287 30 – 39	68	11.6
288 40 – 49	52	8.9
289 ≥ 50	59	10.1
290 Body mass index (kg/m ² - categories)		
291 Obese (≥ 30.0)	58	9.9
292 Overweight (25.0–29.9)	24	4.1
293 Normal weight (18.5–24.9)	236	40.3
294 Underweight (<18.5)	268	45.7
295 <i>S. mansoni</i> infection		
296 Kato-Katz test	347	59.2
297 CCA test	385	65.7
298 KK+CCA*	449	76.6
299 Infection intensity (KK only)		
300 Light	216	36.9
301 Moderate	89	15.2
302 Heavy	42	7.2
303 Soil transmitted helminths		
304 <i>Trichuris trichiura</i>	3	0.5
305 <i>Ascaris lumbricoides</i>	1	0.2
306 Hookworm	4	0.7
307 Clinical findings		
308 Diarrhoea	137	23.4
309 Blood in stool	126	21.5
310 Abdominal pain	309	52.7
311 Hematemesis	5	0.9
312 Ultrasound findings		
313 Hepatomegaly (US)	155	26.5
314 Splenomegaly (US)	148	25.3
315 Ascites	4	0.7
316 Patterns A/B	328	56.0

317	Patterns C/D	213	36.4
318	Patterns E/F	38	6.4
319	Patterns XYZ	7	1.2
320			

321 * KK+CCA, combined any positive result by Kato-Katz and/or by point-of-care circulating
322 cathodic antigen (POC-CCA); KK only, Kato-Katz results only with at least one egg in at least
323 one of two smears.

324 **Morbidity associated with *S. mansoni* infection**

325 The results of the univariable risk analysis of combined approach are presented in Table 2. Male
326 participants were more likely to be infected with *S. mansoni*, but the increased risk was not
327 statistically significant (OR 1.22, 95% CI 0.82–1.81, $P=0.318$). *S. mansoni* infection was observed
328 more frequently in younger age groups, with prevalence peaking among young adults (Figure 3).
329 Participants aged 50 years and older had a statistically significant reduced risk of infection
330 compared to children aged 6–9 years (Table 2, OR 0.49, 95% CI 0.26–0.92, $P=0.024$).

331 Intestinal helminth co-infections were negatively associated with *S. mansoni* infection status
332 among them the association with hookworm infection was statistically significant (OR 0.10, 95%
333 CI 0.01–0.98, $P=0.015$). Study participants who reported an episode of diarrhoea within the
334 preceding two weeks had an increased risk of being infected with *S. mansoni* (OR 1.69, 95% CI
335 1.03–2.78, $P=0.038$).

336 Diagnosed hepatomegaly (OR 1.38, 95% CI 0.87–2.17, $P=0.168$), splenomegaly (OR 1.27, 95%
337 CI 0.81–2.01, $P=0.302$) and E/F liver parenchyma patterns (OR 1.25, 95% CI 0.55–2.84, $P=0.593$)
338 were positively but not significantly associated with an *S. mansoni* infection.

339 The univariable risk analysis for Kato-Katz and POC-CCA diagnosis are given in supplementary
340 Table S1 and S3, respectively. They provided a very similar risk pattern. Noteworthy is that when
341 results of Kato-Katz diagnosis alone are considered male participants had a significant higher risk

342 for a *S. mansoni* infection (Table S1, OR 1.44, 95% CI 1.03–2.03, $P=0.033$) and hepatomegaly
 343 (Table S1, OR 1.41, 95% CI 0.96–2.06, $P=0.079$) was not significantly associated with *S. mansoni*
 344 infection, whereas splenomegaly (Table S1, OR 1.61, 95% CI 1.09–2.39, $P=0.017$) was
 345 significantly associated with *S. mansoni* infection.


346 **Table 2: Morbidity associated with *S. mansoni* infection in the 2017 study.** Results of the
 347 univariable analysis of data from 13 purposively selected villages in Ituri province (n=586).

349	Characteristics	<i>S. mansoni</i> (+)		<i>S. mansoni</i> (-)		OR (95% CI)	p-value
350		N=449		N=137			
351		n	%	n	%		
352	Gender*						
353	Females	257	57.2	85	62.0	1.0	
354	Males	192	42.8	52	38.0	1.22 (0.82–1.81)	0.318
355	Age categories (years)*						
356	6 – 9	92	20.5	31	22.6	1.0	
357	10 – 14	119	26.5	21	15.3	1.61 (0.94–2.76)	0.078
358	15 – 19	54	12.0	13	9.5	1.10 (0.58–2.07)	0.769
359	20 – 29	63	14.0	14	10.2	1.53 (0.81–2.89)	0.184
360	30 – 39	48	10.7	20	14.6	0.77 (0.42–1.42)	0.396
361	40 – 49	35	7.8	17	12.4	0.73 (0.38–1.43)	0.359
362	≥50	38	8.5	21	15.3	0.49 (0.26–0.92)	0.024
363	STH						
364	<i>T. trichiura</i> (Y/N)*	1	0.2	2	1.5	0.15 (0.01–1.69)	0.076
365	<i>A. lumbricoides</i> (Y/N)	1	0.2	0	0.0	na	
366	Hookworm (Y/N)*	4	0.2	3	2.2	0.10 (0.01–0.98)	0.015
367	Anthropometry (BMI)*						
368	Obese (Y/N)	36	8.0	22	16.1	1.0	
369	Overweight (Y/N)	18	4.0	6	4.4	1.83 (0.62–5.40)	0.264
370	Normal weight (Y/N)	183	40.8	53	38.7	2.11 (1.14–3.92)	0.016
371	Underweight (Y/N)	212	47.2	56	40.9	2.31 (1.25–4.28)	0.006
372	Clinical findings						
373	Diarrhoea (Y/N)*	114	25.4	23	16.8	1.69 (1.03–2.78)	0.038
374	Blood in stool (Y/N)	99	22.1	27	19.7	1.15 (0.72–1.86)	0.560
375	Abdominal pain (Y/N)	238	53.0	71	51.8	1.05 (0.72–1.54)	0.808
376	Hematemesis (Y/N)	4	0.9	1	0.7	1.22 (0.14–11.05)	0.858
377	Ultrasound findings						
378	Hepatomegaly (Y/N)*	125	27.8	30	21.9	1.38 (0.87–2.17)	0.168
379	Splenomegaly (Y/N)*	118	26.3	30	21.9	1.27 (0.81–2.01)	0.302
380	Ascites (Y/N)*	2	0.5	2	1.5	0.30 (0.04–2.17)	0.207
381	Pattern A/B (Y/N) *	246	54.8	82	59.9	1.0	
382	Pattern C/D (Y/N)	167	37.2	46	33.6	1.21 (0.80–1.83)	0.363
383	Pattern E/F (Y/N)	30	6.7	8	5.8	1.25 (0.55–2.84)	0.593
384	Pattern XYZ (Y/N)	6	1.3	1	0.7	2.00 (0.24–16.94)	0.517

385
386 * Included in the multivariable analysis. BMI, body mass index (only taken as continuous
387 variable); na, not applicable; Pattern A: normal; Pattern B: “starry sky”; Pattern C: “rings and
388 pipe-stems”; Pattern D “highly echogenic ruff around portal bifurcation”; Pattern E “highly
389 echogenic patches”; Pattern F: “highly echogenic bands and streaks – bird’s claw”; Patterns X, Y,
390 Z indicate pathology different from periportal fibrosis [21].

391
392 **Figure 2: *S. mansoni* infection prevalence by age in the 2017 Ituri province morbidity study**
393 **(n=586).** Overall (green-solid line), female (red-dash line), and male (maroon-long-dash line).

394
395
396 The age distribution of reported diarrhoea and blood in stool, as well as the ultrasonographically
397 assessed hepato- and splenomegaly displayed an age distribution resembling the *S. mansoni*
398 infection with peaks in the adolescent and adult age groups (Figure 3).



399
400 **Figure 3: Age distribution of intestinal and hepatosplenic morbidity in the 2017 Ituri**
401 **province morbidity study (n=586).** Hepatomegaly (olive-solid line), splenomegaly (cranberry-

402 solid line), diarrhoea (magenta-long-dash line), and blood in stool (red-short-dash-dot line).
403
404

405

406 The risk analysis took in account results of the combined Kato-Katz and POC-CCA diagnostic
407 approach (Table 3). These results were broadly consistent when using Kato-Katz or POC-CCA

408 alone. However, there were some discrepancies. First, intestinal morbidity indicator, such as
409 diarrhoea, was significantly associated with an *S. mansoni* infection (OR 1.69, 95% CI 1.03–2.78,
410 $P=0.038$). This is also the case when results of Kato-Katz test alone are taken in account (OR 1.85,
411 95% CI 1.22–2.79, $P=0.003$). However, using results of POC-CCA alone, the association became
412 not significant (OR 1.42, 95% CI 0.93–2.16, $P=0.101$). Other indicators including the presence of
413 blood in stool, abdominal pain, and history of hematemesis were not associated regardless of the
414 diagnostic approaches used. Second, hepatomegaly was not significantly associated with an *S.*
415 *mansoni* infection using the combined (OR 1.38, 95% CI 0.87–2.17, $P=0.168$), even using POC-
416 CCA (OR 1.33, 95% CI 0.89–1.98, $P=0.158$), or Kato-Katz test alone (OR 1.41, 95% CI 0.96–
417 2.06, $P=0.079$). Splenomegaly was significantly associated with an *S. mansoni* infection using
418 Kato-Katz test alone (OR 1.61, 95% CI 1.09–2.39, $P=0.017$). The association was not significant
419 when using the combined and POC-CCA diagnostic approaches (OR 1.27, 95% CI 0.81–2.01,
420 $P=0.302$) and (OR 1.17, 95% CI 0.78–1.74, $P=0.451$), respectively. Third, an abnormal liver
421 parenchyma pathology (combined patterns E/F) was significantly associated with *S. mansoni*
422 infection when using either Kato-Katz test alone (OR 2.25, 95% CI 1.05–4.80, $P=0.032$). The
423 association was not significant when using POC-CCA alone or the combined approaches (OR 1.20,
424 95% CI 0.58–2.47, $P=0.618$) and (OR 1.25, 95% CI 0.55–2.84, $P=0.593$), respectively.

425 Ten variables were included in the multivariable logistic regression analysis, the results of which
426 are displayed in Table 3. Age was negatively associated with *S. mansoni* infection (adjusted odds
427 ratio [aOR] 0.98; 95% CI 0.96–0.99, $P=<0.001$) while gender showed not significantly associated
428 with the *S. mansoni* infection (aOR 1.15; 95% CI 0.74–1.79, $P=0.524$).

429 Of the morbidity indicators investigated, diarrhoea (aOR 1.69; 95% CI 0.99–2.89, $P=0.053$) and
430 hepatomegaly (aOR 1.58; 95% CI 0.96–2.61, $P=0.071$) were associated with *S. mansoni* infection


431 with a borderline significance level. Patients with abnormal liver parenchyma patterns (aOR 1.13;
432 95% CI 0.98–1.31, $P=0.100$) did not have an increased risk for *S. mansoni* infection.

433 **Table 3. Morbidity associated with *S. mansoni* infection in the 2017 study based on Kato-**
434 **Katz and POC-CCA diagnostic approach.** Results of the multivariable analysis of data from 13
435 purposively selected villages in Ituri province (n=586).

Risk factors	aOR (95% CI)	Std. Err.	z	p-value
Demographic risk factors				
Age	0.98 (0.96–0.99)	0.006	-3.64	<0.001
Gender (Male/Female)	1.15 (0.74–1.79)	0.259	0.64	0.524
Anthropometric risk factors				
BMI	1.00 (0.95–1.06)	0.027	0.15	0.878
Clinical finding				
Diarrhoea	1.69 (0.99–2.89)	0.461	1.94	0.053
Blood in stool	0.90 (0.54–1.50)	0.237	-0.41	0.683
Ultrasound findings				
Hepatomegaly (Yes/No)	1.58 (0.96–2.61)	0.404	1.80	0.071
Splenomegaly (Yes/No)	0.91 (0.55–1.50)	0.230	-0.37	0.712
Ascites (Yes/No)	0.21 (0.03–1.69)	0.225	-1.46	0.144
Liver pathology (Yes/No)	1.13 (0.98–1.31)	0.085	1.65	0.100
Co-infection				
Hookworm (Yes/No)	0.08 (0.01–0.81)	0.093	-2.14	0.033

459 aOR: adjusted odds ratio in multivariable analysis; CI: confidence interval. BMI, body mass index
460 (only taken as continuous variable).

462 At the village level, the prevalence of hepatomegaly (Figure 4) and splenomegaly (Figure 5)
463 increased with the prevalence of *S. mansoni* infection. Four patients were diagnosed with ascites;
464 all of whom were residents of villages where overall *S. mansoni* prevalence exceeded 80%.




465

466 **Figure 4: Association of hepatomegaly and *S. mansoni* infection prevalence at village level in**
467 **the 2017 Ituri morbidity study (n=586).**

468

469



470
471 **Figure 5: Association of splenomegaly and *S. mansoni* infection prevalence at village level in**
472 **the 2017 Ituri morbidity study (n=586).**

473
474
475 *S. mansoni* infection intensity varied greatly among individuals, with a maximum of 4,497.6 EPG
476 and a mean infection intensity of 109.7 EPG. Table 4 presents the infection intensity according to
477 gender, age, helminth co-infection and morbidity categories. Infection intensity levels were similar
478 in the two gender groups ($P=0.198$). The age distribution of the infection intensity levels followed
479 the age-infection prevalence curve. Heavy-intensity infections were mostly found (12.9%) among
480 adolescents aged 10–14 years ,while no one in the oldest age group (50 years and older) had a
481 heavy-intensity infection ($P=0006$). Heavy-intensity infections were significantly higher among

482 patients co-infected with *Ascaris lumbricoides* (13.0%, $P=0.005$) and underweight participants
483 (10.1%, $P=0.033$).

484 There was a significantly higher prevalence of reported diarrhoea (40.5%, $P=0.004$) and blood in
485 the stool (52.4%, $P<0.001$) among patients in the heavy-intensity infection group compared to the
486 other infection intensity groups.

487 Among patients with heavy-intensity infections, the prevalence of splenomegaly (57.1%) was
488 significantly higher than among other infection intensity groups ($P<0.001$), while the prevalence
489 of hepatomegaly (38.1%) was not statistically different compared with the other infection intensity
490 groups ($P=0.073$). When stratified by age, patients with an enlarged liver and/or spleen bore a
491 higher infection intensity burden compared to those with a normal-sized liver and spleen in the
492 same age group (Figure 6 and Table S6). In general, younger patients (children: aged <18 years)
493 experienced more high-intensity infections compared to those in older age groups (adults: aged \geq
494 18 years).


495 **Table 4: *S. mansoni* infection intensity by morbidity in the 2017 study.** Study conducted in 13
 496 purposively selected villages in Ituri province (n=586). Only results of the Kato-Katz test have
 497 been considered in this analysis.

Characteristics	<i>S. mansoni</i> infection intensity								χ^2	p-value
	Negative		Light		Moderate		Heavy			
	n	%	n	%	n	%	n	%		
Overall	239	40.8	216	36.9	89	15.2	42	7.2		
Gender										
Females	152	44.4	117	34.2	50	14.6	23	6.7		
Males	87	35.7	99	40.6	39	16.0	19	7.8	4.66	0.198
Age categories (years)										
6 – 9	50	40.7	47	38.2	18	14.6	8	6.5		
10 – 14	49	35.0	49	35.0	24	17.1	18	12.9		
15 – 19	19	28.0	25	37.3	17	25.4	6	9.0		
20 – 29	27	35.0	32	41.6	11	14.3	7	9.1		
30 – 39	31	45.6	26	38.2	9	13.3	2	2.9		
40 – 49	27	51.9	18	34.6	6	11.6	1	1.9		
≥50	36	61.0	19	32.2	4	6.8	0	0.0	36.68	0.006
Soil-transmitted helminths										
<i>T. trichiura</i> (Y/N)	2	0.8	1	0.5	0	0.0	0	0.0	1.18	0.758
<i>Ascaris</i> (Y/N)	0	0.0	0	0.0	0	0.0	1	2.4	13.0	0.005
Hookworm (Y/N)	3	1.3	1	0.5	0	0.0	0	0.0	2.21	0.530
Anthropometry (BMI)										
Obese	33	56.9	20	34.5	4	6.9	1	1.7		
Overweight	13	54.2	9	37.5	2	8.3	0	0.0		
Normal weight	96	40.7	89	37.7	37	15.7	14	5.9		
Underweight	97	36.2	98	36.5	46	17.2	27	10.1	18.15	0.033
Clinical findings										
Diarrhoea (Y/N)	41	17.2	56	25.9	23	25.8	17	40.5	13.11	0.004
Blood in stool (Y/N)	42	17.6	32	14.8	30	33.7	22	52.4	39.49	<0.001
Abdom. pain (Y/N)	124	51.9	107	49.5	52	58.4	26	61.9	3.53	0.317
Hematemesis (Y/N)	3	1.3	1	0.5	1	1.1	0	0.0	1.28	0.733
Ultrasound findings										
Hepatomegaly (Y/N)	54	22.6	65	30.1	20	22.5	16	38.1	6.95	0.073
Splenomegaly (Y/N)	48	20.1	48	22.2	28	31.5	24	57.1	28.88	<0.001
Ascites (Y/N)	3	1.3	0	0.0	1	1.1	0	0.0	3.19	0.364
Pattern A/B (Y/N)	146	44.5	120	36.6	43	13.1	19	5.8		
Pattern C/D (Y/N)	80	37.6	79	37.1	37	17.4	17	8.0		
Pattern E/F (Y/N)	10	26.3	13	34.2	9	23.7	6	15.8		
Pattern XYZ (Y/N)	3	42.9	4	57.1	0	0.0	0	0.0	14.46	0.107

537 BMI, body mass index; Abdom.: abdominal. Pattern A: normal; Pattern B: “starry sky”; Pattern
 538 C: “rings and pipe-stems”; Pattern D “highly echogenic ruff around portal bifurcation”; Pattern E
 539 “highly echogenic patches”; Pattern F: “highly echogenic bands and streaks – bird’s claw”;
 540 Patterns X, Y, Z indicate pathology different from periportal fibrosis. [21].

541 *S. mansoni* infection intensity varied considerably among patients with different liver parenchyma
542 pathologies (Tables S5 and S7). In general, more heavy-intensity infections were observed among
543 patients with more severe liver morbidity patterns. That is, the number of individuals with heavy-
544 intensity infections increased with the severity of the liver parenchyma pattern, from normal liver
545 parenchyma patterns A and B (5.8%) to the most severe “bird’s claw” patterns E and F (15.8%).
546 The association was not statistically significant ($P=0.107$). When stratified by age, a clear
547 association emerged between increased number of high-intensity infections and increasingly
548 abnormal liver pathologies (Figure 7). Liver parenchyma worsened, from A and B normal patterns
549 to C and D mild PPF patterns, and to E and F severe PPF patterns, the median infection intensity
550 increased. However, taken alone, patients with pattern F had similar- or lower-intensity infections
551 than patients with less severe morbidity patterns (Table S7).

552




553

554

555 **Figure 6: *S. mansoni* infection intensity by hepatomegaly and splenomegaly and age in the**
556 **2017 Ituri morbidity study (n=586). Hepatomegaly (green) and splenomegaly (cranberry).**

557

558



559
560
561 **Figure 7: *S. mansoni* infection intensity by liver parenchyma patterns and age in the 2017**
562 **Ituri morbidity study (n=586).** Patterns A&B: normal (lime); Patterns C/D: mild PPF (magenta)
563 ; Pattern E/F: severe PPF (red); Pattern XYZ: other no PPF pathologies (purple).

564

565

566

567 **Discussion**

568 The focus of the World Health Organization's roadmap for neglected tropical diseases 2012-2030
569 with regard to schistosomiasis is control of morbidity. This is especially the case in the African
570 region where transmission levels in several countries, including the Democratic Republic of the
571 Congo are high, and elimination is not yet scheduled. The key recommended strategic approach is
572 preventive chemotherapy with praziquantel. Mass treatment of population exposed to risk of
573 infection, at regular intervals, prevents the development of high-intensity infections and hence, of
574 morbidity [23, 24].

575 Our study provides, for the first time, comprehensive baseline data showing a high intestinal and
576 hepatosplenic morbidity burden in Ituri province; a burden that is associated with *S. mansoni*
577 infection at both the individual and community level. At present, we cannot quantify the extent to
578 which *S. mansoni* infection alone is responsible for the observed morbidity (or whether other
579 infections contribute). To answer this question, additional investigations are needed. However, the
580 high degree of intestinal and hepatosplenic morbidity present in Ituri province warrants immediate
581 and comprehensive control activities.

582 Although minimizing morbidity is the target of schistosomiasis control efforts, control programmes
583 rarely collect (baseline) and monitor morbidity data. Instead, they largely rely on monitoring
584 infection intensities, which are linked to morbidity and much easier to assess than intestinal and
585 hepatosplenic morbidity. Consequently, little is known about the morbidity burden of
586 schistosomiasis [6].

587 Control programmes have been conducted successfully in colonial time, even with means that
588 today may be considered outdated. However, with these means the disease was well controlled

589 [15]. Since the independence of the country, no large-scale activity aimed at combating the disease
590 has ever been undertaken until 2012. Since this date, a public control program targeting school
591 children started in the country and it was launched in the Ituri province in 2016.

592 In this study, we assessed the magnitude of the intestinal and hepatosplenic morbidity burden in
593 Ituri province, DRC, and investigated its associations with *S. mansoni* infection status. To that end,
594 we conducted a cross-sectional study in 13 *S. mansoni* endemic villages. We enrolled all household
595 member six years and older and assessed their *S. mansoni* infection status and their intestinal and
596 hepatosplenic morbidity.

597 We found a high degree of intestinal and hepatosplenic morbidity. About one quarter of the study
598 participants reported diarrhoea (23.4%) and blood in the stool (21.5%). Upon ultrasonography
599 examination, almost one-quarter was diagnosed with hepatomegaly (26.5%); almost two-thirds
600 (25.3%) had splenomegaly, and more than half (42.8%) had abnormal liver parenchyma (pattern
601 C–F). Five patients reported an experience of hematemesis and four patients had ascites.

602 In our study population, we found a high prevalence of *S. mansoni* infection (76.6%). As POC-
603 CCA does not provide information on infection intensity, the analysis of infection intensity was
604 done based on the Kato-Katz results only. Light-, moderate- and heavy-intensity infections were
605 diagnosed in high frequencies of 36.9%, 15.2% and 7.2%, respectively. Only few cases of soil-
606 transmitted helminths with an expected very small impact on the morbidity were diagnosed during
607 this study. *S. mansoni* infection prevalence and intensity was highest in the adolescent and young
608 adult age groups. The prevalence of intestinal and hepatosplenic morbidity indicators showed a
609 very similar age distribution (although hepato- and splenomegaly peaked in older age groups), and
610 at village level, hepatosplenic morbidity prevalence increased with infection prevalence. Both

611 observations suggesting a close link between morbidity and *S. mansoni* infection. Furthermore, at
612 individual level, we found an increased risk of hepatomegaly and splenomegaly in *S. mansoni*-
613 infected patients, confirming the association found at village level and the similarly shaped age
614 distributions. The findings are also consistent with documented hepatosplenic morbidity associated
615 with *S. mansoni* infection [25, 26]. Hence, providing further evidence that *S. mansoni* infection is
616 a major contributor to the overall observed morbidity.

617 We found three notable differences in the risk results when relying on the diagnostic results from
618 the Kato-Katz technique only. However, as we needed to get the respective advantages of both
619 more specific (Kato-Katz) and more sensitive (POC-CCA) tests, we considered the results of the
620 Kato-Katz + POC-CCA combined approach. First, reported diarrhoea was significantly associated
621 with *S. mansoni* infection; second, pathological changes of the liver parenchyma were associated
622 with *S. mansoni* infection as was hepatomegaly; and, third, splenomegaly was not associated with
623 *S. mansoni* infection. Using the Kato-Katz technique alone to diagnose *S. mansoni* infection
624 reduces the overall sensitivity of the diagnostic approach due to the low sensitivity of the technique
625 itself [27, 28]. Hence, on average, those diagnosed with an *S. mansoni* infection are more likely to
626 have a higher infection intensity in comparison to the combined diagnostic approach. From these
627 observations, we see that subtle morbidity increases — such as reported diarrhoea and pathological
628 changes in the liver parenchyma — become statistically significant. Indeed, for both morbidity
629 indicators, we observed an association with *S. mansoni* infection intensity. Patients with diarrhoea
630 had the highest prevalence of heavy-intensity infections (Table 2) and those with abnormal liver
631 parenchyma patterns E–F had the highest mean infection intensities (Figure 4 and Table S7).
632 However, the importance of the association of parasitological diagnosis with morbidity was much
633 more at the community (village) level than at the individual level.

634 In our study, we found that patients with abnormal liver parenchyma pattern F displayed lower *S.*
635 *mansoni*'s infection intensity and risk compared to the E pattern. The highly echogenic bands and
636 streaks corresponding to the pattern F extend from main portal vein and its bifurcation to the liver
637 surface. Most habitually, this pattern is manifested in very advanced cases of liver fibrosis and is
638 frequently conglomerated with other changes [21]. Patients who displayed this pattern were often
639 older, thus, they have little exposure to water contact, and some have been already treated once,
640 twice or more times with praziquantel. Consequently, they may be free of infection or may have
641 light infection intensities. It is also known that treatment with praziquantel could not halt
642 progression of organ damage in some individuals. This situation may be due to immunological and
643 genetic factors as well as other factors, including malaria, viral hepatitis and/or concomitant alcohol
644 consumption [5, 29-31].

645 Quantifying schistosomiasis morbidity is a challenging [6, 32] and controversial matter [4].
646 Morbidity associated with *Schistosoma* infection is unspecific. Hence, the observed morbidity
647 pattern might be provoked partially by or in combination with other pathogens, such as other
648 helminth species, protozoa, bacteria and viruses. Given that multiple infections are frequent in
649 tropical Africa, a combination of infections is most likely responsible for the observed morbidity.
650 In Ituri province, other parasitic infections, such as malaria (i.e. *Plasmodium falciparum*), and other
651 infections with hepatosplenic affinity, such as viral hepatitis, are prevalent [3, 5, 33, 34] and may
652 have contributed to the hepatosplenic morbidity pattern observed. The time gap between infection
653 and the occurrence of measurable morbidity further complicates efforts to assess the association
654 between infection and morbidity. Furthermore, organomegaly is sometimes described as normally
655 present in children; it then regresses and disappears in adulthood [5, 35-37].

656 Nevertheless, these findings cannot in any way reduce the value of abdominal ultrasound in the
657 diagnosis of liver pathologies associated with *S. mansoni* infection. However, ultrasonography
658 devices are rarely available in the poor-resource settings. In Ituri province, the device may be found
659 only in the provincial hospital and in some district hospitals and private clinics. In our field work,
660 we found that the use of portable devices is feasible in the villages. However, in the remotest rural
661 areas, the usage is challenging as electricity was not available. It requires additional equipment
662 such as solar panels and rechargeable batteries. Despite of these shortcomings, abdominal
663 ultrasound adds crucial information on the liver morbidity in the community and hence,
664 indispensable information on the public health burden of *S. mansoni* infection [38]. Furthermore,
665 severe cases are likely to be early diagnosed and adequately addressed.

666 In our study, we encountered patients with severe complications from *S. mansoni* infection, which
667 further underscore the importance of the infection's morbidity burden. Four people (0.9%) reported
668 a history of hematemesis and two people (0.5%) with ascites. The finding appears to corroborate
669 the health service's statistics report from the Angumu health district (on the shore of Lake Albert),
670 which declares that hematemesis is a frequent medical emergency and that adults have died after
671 vomiting blood in this area. Oesophageal varices remain silent until they rupture and irreversible
672 damage occurs [34]. Angumu health district is a remote area and well known for its high blood
673 transfusion rates. Patients vomiting blood often reach the hospital too late, leading to the worst
674 medical outcome.

675 The morbidity levels we observed are consistent with those measured by Ongom and Bradley [18],
676 who found serious morbidity, including diarrhoea and abdominal pain, in a schistosomiasis
677 endemic community on Lake Albert in Uganda. Other studies of *S. mansoni* endemic communities
678 outside of the DRC present similar morbidity levels [37-39]. Very few studies of morbidity due to

679 schistosome infection in DRC exist [34, 40]. Our study contributes to the country's knowledge
680 base and may offer a baseline for future intervention studies to determine the exact extent of
681 morbidity associated with *S. mansoni* infection.

682 Our study, as many others, presents some limitations. We conducted our study in purposively
683 sampled villages known to have a high prevalence of *S. mansoni*. Thus, the examined population
684 is not representative of the entire province but rather of high transmission areas. Furthermore,
685 ongoing civil unrest in Ituri province creates a challenging security situation, which only afforded
686 us a short time in each village. For this reason, only one stool sample could be collected from each
687 study participant. Finally, limited available resources did not allow us to examine participants for
688 parasitic, bacterial and viral co-infections, which could have helped to better explain the degree of
689 morbidity linked to *S. mansoni* infection.

690 Other limitations include the lack of the diagnosis of blood coinfections and the definition of the
691 body mass index (BMI) cut-off that did not take in account variations among the study population
692 as it is recommended [41]. Concerning the first limitation, we needed to exclude as much as
693 possible invasive procedures and vulnerable individuals. Indeed, blood sampling is very sensitive
694 in our study area as population is reluctant to blood drawing. It would have required a lot of effort
695 and time for the study. In addition, the compliance of the study participants would have been greatly
696 reduced. Hence, coinfections such as malaria [42], viral hepatitis [43], human immune virus (HIV)
697 as well as other similar diseases endemic in the province were not diagnosed. However, despite not
698 having excluded these confounding factors, the association of *S. mansoni* infection with
699 hepatosplenic and intestinal morbidity remains highly significant.

700 As for the BMI cut-off values, we randomly defined in four categories including underweight
701 (<18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), and obese (≥ 30
702 kg/m²) population. This random clustering could be likely to introduce a selection bias in our
703 results. However, in the risk analysis, we used the BMI as a continuous variable instead of the
704 categorical one.

705 **Conclusion**

706 Schistosomiasis mansoni is an important public health problem in the Ituri province and an
707 appropriate control is not yet being carried. The existing public programme for the control of the
708 disease was launched in 2016 in the province. It is based on preventive chemotherapy and aims at
709 controlling infection among school children. Our results show that both infection and the related
710 morbidity are very high in the province. This situation calls to most vigorous and efficient control
711 measures to correctly address this scourge.

712 **Acknowledgements**

713 We are grateful to all the study participants both in 2016 and in 2017. Our sincere thanks
714 to the research teams in this two-years period. We thank the Provincial Health Division officers,
715 all the Health Districts officers, and the Institut Supérieur des Techniques Médicales de Nyankunde
716 staff for their support and the local authorities for their support during the fieldwork.

717

718

719 **References**

- 720
721 1. WHO. Schistosomiasis Key facts. 2020.
- 722 2. Elbaz T, Esmat G. Hepatic and intestinal schistosomiasis: review. *J Adv Res.* 2013;4(5):445-52. Epub
723 2013/09/01. doi: 10.1016/j.jare.2012.12.001. PubMed PMID: 25685451; PubMed Central PMCID:
724 PMCPMC4293886.
- 725 3. Tukahebwa EM, Magnussen P, Madsen H, Kabatereine NB, Nuwaha F, Wilson S, et al. A Very High
726 Infection Intensity of *Schistosoma mansoni* in a Ugandan Lake Victoria Fishing Community Is Required for
727 Association with Highly Prevalent Organ Related Morbidity. *Plos Neglect Trop D.* 2013;7(7). doi: ARTN
728 e2268
10.1371/journal.pntd.0002268. PubMed PMID: WOS:000322321500006.
- 729 4. Asztely MS, Eriksson B, Gabone RM, Nilsson LA. Is ultrasonography useful for population studies
730 on schistosomiasis mansoni? An evaluation based on a survey on a population from Kome Island, Tanzania.
731 *Acta Radiol Open.* 2016;5(12):2058460116686392. Epub 2017/03/14. doi: 10.1177/2058460116686392.
732 PubMed PMID: 28286672; PubMed Central PMCID: PMCPMC5330413.
- 733 5. Kabatereine NB, Kemijumbi J, Ouma JH, Kariuki HC, Richter J, Kadzo H, et al. Epidemiology and
734 morbidity of *Schistosoma mansoni* infection in a fishing community along Lake Albert in Uganda. *T Roy Soc*
735 *Trop Med H.* 2004;98(12):711-8. doi: 10.1016/j.trstmh.2004.06.003. PubMed PMID:
736 WOS:000224900600004.
- 737 6. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, et al.
738 Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop.*
739 2003;86(2-3):125-39. Epub 2003/05/15. doi: 10.1016/s0001-706x(03)00029-9. PubMed PMID: 12745133.
- 740 7. Savioli L, Albonico M, Engels D, Montresor A. Progress in the prevention and control of
741 schistosomiasis and soil-transmitted helminthiasis. *Parasitol Int.* 2004;53(2):103-13. doi:
742 10.1016/j.parint.2004.01.001. PubMed PMID: WOS:000221210900001.
- 743 8. Savioli L, Stansfield S, Bundy DAP, Mitchell A, Bhatia R, Engels D, et al. Schistosomiasis and soil-
744 transmitted helminth infections: forging control efforts. *T Roy Soc Trop Med H.* 2002;96(6):577-9. doi: Doi
745 10.1016/S0035-9203(02)90316-0. PubMed PMID: WOS:000181165200001.
- 746 9. Gray DJ, Ross AG, Li YS, McManus DP. CLINICAL REVIEW Diagnosis and management of
747 schistosomiasis. *Brit Med J.* 2011;342. doi: ARTN d2651
10.1136/bmj.d2651. PubMed PMID: WOS:000290951700001.
- 748 10. WHO. Schistosomiasis: population requiring preventive chemotherapy and number of people
749 treated in 2010. 2012;4(87):37-44.
- 750 11. Rimoin AW, Hotez PJ. NTDs in the Heart of Darkness: The Democratic Republic of Congo's
751 Unknown Burden of Neglected Tropical Diseases. *Plos Neglect Trop D.* 2013;7(7). doi: ARTN e2118
10.1371/journal.pntd.0002118. PubMed PMID: WOS:000322321500001.
- 752 12. Madinga J, Linsuke S, Mpabanzi L, Meurs L, Kanobana K, Speybroeck N, et al. Schistosomiasis in
753 the Democratic Republic of Congo: a literature review. *Parasite Vector.* 2015;8. doi: ARTN 601
10.1186/s13071-015-1206-6. PubMed PMID: WOS:000365330600002.
- 754 13. Gryseels B, Polderman AM. The morbidity of schistosomiasis mansoni in Maniema (Zaire). *Trans R*
755 *Soc Trop Med Hyg.* 1987;81(2):202-9. Epub 1987/01/01. doi: 10.1016/0035-9203(87)90215-x. PubMed
756 PMID: 3113002.
- 757 14. Polderman AM, Gryseels B, De Caluwe P. Cure rates and egg reduction in treatment of intestinal
758 schistosomiasis with oxamniquine and praziquantel in Maniema, Zaire. *Trans R Soc Trop Med Hyg.*
759 1988;82(1):115-6. Epub 1988/01/01. PubMed PMID: 3140441.

- 764 15. WHO. Les bilharzioses humaines au Congo Belge et au Ruanda-Urundi. 1954.
- 765 16. Doumenge JP, Mott KE. Global distribution of schistosomiasis: CEGET/WHO atlas. World Health
766 Stat Q. 1984;37(2):186-99. Epub 1984/01/01. PubMed PMID: 6541400.
- 767 17. Muller G, Murenzi JK, Tulu R. Prevalence of Intestinal Schistosomiasis in Zairian and Ugandan
768 Children in the Aru Zone of Upper Zaire. Ann Soc Belg Med Tr. 1986;66(3):225-33. PubMed PMID:
769 WOS:A1986F477300004.
- 770 18. Ongom VL, Owor R, Grundy R, Bradley DJ. Epidemiology and Consequences of Schistosoma-
771 Mansoni Infection in West Nile, Uganda .2. Hospital Investigation of a Sample from Panyagoro Community.
772 T Roy Soc Trop Med H. 1972;66(6):852-63. doi: Doi 10.1016/0035-9203(72)90119-8. PubMed PMID:
773 WOS:A1972O459900004.
- 774 19. WHO. Preventive chemotherapy in human helminthiasis. 2006.
- 775 20. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in
776 Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1972;14(6):397-400. Epub 1972/11/01. PubMed
777 PMID: 4675644.
- 778 21. Richter J, Domingues ALC, Barata CH, Prata AR, Lambertucci JR. Report of the second satellite
779 symposium on ultrasound in schistosomiasis. Mem I Oswaldo Cruz. 2001;96:151-6. doi: Doi
780 10.1590/S0074-02762001000900023. PubMed PMID: WOS:000171200700023.
- 781 22. Berhe N, Geitung JT, Medhin G, Gundersen SG. Large scale evaluation of WHO's ultrasonographic
782 staging system of schistosomal periportal fibrosis in Ethiopia. Trop Med Int Health. 2006;11(8):1286-94.
783 Epub 2006/08/15. doi: 10.1111/j.1365-3156.2006.01665.x. PubMed PMID: 16903891.
- 784 23. WHO. WHO's roadmap 2012-2030. 2012.
- 785 24. WHO. WHO's Schistosomiasis: progress report 2001 - 2011, strategic plan 2012 – 2020. 2013.
- 786 25. Kaatano GM, Min D-Y, Siza JE, Yong T-S, Chai J-Y, Ko Y, et al. Schistosoma mansoni-Related
787 Hepatosplenic Morbidity in Adult Population on Kome Island, Sengerema District, Tanzania. Korean J
788 Parasitol. 2015;53(5):545-51. PubMed PMID: Medline:26537033.
- 789 26. Booth M, Vennervald BJ, Kabatereine NB, Kazibwe F, Ouma JH, Kariuki CH, et al. Hepatosplenic
790 morbidity in two neighbouring communities in Uganda with high levels of Schistosoma mansoni infection
791 but very different durations of residence. T Roy Soc Trop Med H. 2004;98(2):125-36. PubMed PMID:
792 Medline:14964813.
- 793 27. Maurice Mutro Nigo GBS-B, Manuel Battegay, Peter Odermatt, Patrick Hunziker. Schistosomiasis:
794 from established diagnostic assays to emerging micro/nanotechnology-based rapid field testing for clinical
795 management and epidemiology. Prec Nanomed. 2020;3(1):439-58. doi: 10.33218.
- 796 28. Mazigo HD, Heukelbach J. Diagnostic Performance of Kato Katz Technique and Point-of-Care
797 Circulating Cathodic Antigen Rapid Test in Diagnosing Schistosoma mansoni Infection in HIV-1 Co-Infected
798 Adults on the Shoreline of Lake Victoria, Tanzania. Tropical medicine and infectious disease. 2018;3(2).
799 PubMed PMID: Medline:30274450.
- 800 29. Kinung'hi SM, Mazigo HD, Dunne DW, Kepha S, Kaatano G, Kishamawe C, et al. Coinfection of
801 intestinal schistosomiasis and malaria and association with haemoglobin levels and nutritional status in
802 school children in Mara region, Northwestern Tanzania: a cross-sectional exploratory study. BMC Res
803 Notes. 2017;10(1):583. Epub 2017/11/11. doi: 10.1186/s13104-017-2904-2. PubMed PMID: 29121978;
804 PubMed Central PMCID: PMC5679344.
- 805 30. Mazigo HD, Dunne DW, Morona D, Lutufyo TE, Kinung'hi SM, Kaatano G, et al. Periportal fibrosis,
806 liver and spleen sizes among S. mansoni mono or co-infected individuals with human immunodeficiency
807 virus-1 in fishing villages along Lake Victoria shores, North-Western, Tanzania. Parasit Vectors. 2015;8:260.
808 Epub 2015/05/08. doi: 10.1186/s13071-015-0876-4. PubMed PMID: 25948238; PubMed Central PMCID:
809 PMC4424565.
- 810 31. Mazigo HD, Kepha S, Kaatano GM, Kinung'hi SM. Co-infection of Schistosoma mansoni/hepatitis C
811 virus and their associated factors among adult individuals living in fishing villages, north-western Tanzania.

- 812 Bmc Infect Dis. 2017;17(1):668. Epub 2017/10/12. doi: 10.1186/s12879-017-2780-3. PubMed PMID:
813 29017483; PubMed Central PMCID: PMCPMC5635496.
- 814 32. Samuels AM, Matey E, Mwinzi PNM, Wiegand RE, Muchiri G, Ileri E, et al. Schistosoma mansoni
815 morbidity among school-aged children: a SCORE project in Kenya. The American journal of tropical
816 medicine and hygiene. 2012;87(5):874-82. PubMed PMID: Medline:22987651.
- 817 33. Davis SM, Wiegand RE, Mulama F, Kareko EI, Harris R, Ochola E, et al. Morbidity associated with
818 schistosomiasis before and after treatment in young children in Rusinga Island, western Kenya. Am J Trop
819 Med Hyg. 2015;92(5):952-8. Epub 2015/03/12. doi: 10.4269/ajtmh.14-0346. PubMed PMID: 25758651;
820 PubMed Central PMCID: PMCPMC4426584.
- 821 34. Gryseels B, Polderman AM. The Morbidity of Schistosomiasis-Mansoni in Maniema (Zaire). T Roy
822 Soc Trop Med H. 1987;81(2):202-9. doi: Doi 10.1016/0035-9203(87)90215-X. PubMed PMID:
823 WOS:A1987H167300011.
- 824 35. Gryseels B. Morbidity and Dynamics of Schistosomiasis after Chemotherapy - Implications for
825 Control. Eur J Pharmacol. 1990;183(3):670-. doi: Doi 10.1016/0014-2999(90)92457-T. PubMed PMID:
826 WOS:A1990DT67400022.
- 827 36. Gryseels B, Nkulikyinka L. The Morbidity of Schistosomiasis-Mansoni in the Highland Focus of Lake
828 Cohoha, Burundi. T Roy Soc Trop Med H. 1990;84(4):542-7. doi: Doi 10.1016/0035-9203(90)90033-B.
829 PubMed PMID: WOS:A1990DX19600025.
- 830 37. Abdel-Wahab MF, Esmat G, El-Boraey Y, Ramzy I, Medhat E, Strickland GT. The epidemiology of
831 schistosomiasis in Egypt: Methods, training, and quality control of clinical and ultrasound examinations.
832 Am J Trop Med Hyg. 2000;62(2):17-20. doi: DOI 10.4269/ajtmh.2000.62.17. PubMed PMID:
833 WOS:000086917200005.
- 834 38. El-Khoby T, Galal N, Fenwick A, Barakat R, El-Hawey A, Nooman Z, et al. The epidemiology of
835 schistosomiasis in Egypt: summary findings in nine governorates. Am J Trop Med Hyg. 2000;62(2 Suppl):88-
836 99. Epub 2000/05/17. doi: 10.4269/ajtmh.2000.62.88. PubMed PMID: 10813505.
- 837 39. El-Hawey AM, Amr MM, Abdel-Rahman AH, El-Ibiary SA, Agina AM, Abdel-Hafez MA, et al. The
838 epidemiology of schistosomiasis in Egypt: Gharbia Governorate. Am J Trop Med Hyg. 2000;62(2 Suppl):42-
839 8. Epub 2000/05/17. doi: 10.4269/ajtmh.2000.62.42. PubMed PMID: 10813499.
- 840 40. Gryseels B, Polderman AM. Schistosoma-Mansoni Morbidity in 3 Central-Africa Foci -
841 Intrapopulation Vs Interpopulation Analysis. Trop Med Parasitol. 1987;38(3):263-. PubMed PMID:
842 WOS:A1987K334600091.
- 843 41. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight
844 and obesity worldwide: international survey. BMJ. 2000;320(7244):1240-3. Epub 2000/05/08. doi:
845 10.1136/bmj.320.7244.1240. PubMed PMID: 10797032; PubMed Central PMCID: PMCPMC27365.
- 846 42. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. Pfhrp2-Deleted
847 Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-sectional
848 Survey. The Journal of infectious diseases. 2017;216(1):36-44. PubMed PMID: Medline:28177502.
- 849 43. Makiala-Mandanda S, Le Gal F, Ngwaka-Matsung N, Ahuka-Mundeke S, Onanga R, Bivigou-
850 Mboumba B, et al. High Prevalence and Diversity of Hepatitis Viruses in Suspected Cases of Yellow Fever
851 in the Democratic Republic of Congo. J Clin Microbiol. 2017;55(5):1299-312. PubMed PMID:
852 Medline:28202798.

853
854

855

856 **Funding**

857 The study was funded by private funds (Poverty Fund, Switzerland). The funders had no role in
858 study design, data collection and data analysis, decision to publish, or preparation of the
859 manuscript.

860

861 **Competing interest**

862 No authors have competing interests.

863

864 **Supplementary information captions**

865 **Tables**

866

867 **Table S1: Univariable associations with *S. mansoni* infection in the 2017 morbidity study.**

868 Study conducted in 13 purposively selected villages in Ituri province (n=586). Only
869 diagnostic results of Kato-Katz (KK) test have been considered.

870

871 **Table S2: Risk factors for morbidity due to *Schistosoma mansoni* infection, 2017 study.**

872 Results of the multivariable analysis of risk factors for morbidity due to *Schistosoma*
873 *mansoni* infection among participants from 13 villages in Ituri province (n=586).
874 Only diagnostic results of Kato-Katz (KK) test have been considered.

875 **Table S3: Univariable associations with *S. mansoni* infection in the 2017 morbidity study.**

876 Study conducted in 13 purposively selected villages in Ituri province (n=586). Only
877 diagnostic results of the point-of-care circulating cathodic antigen (POC-CCA) test
878 have been considered.

879

880 **Table S4: Risk factors for morbidity due to *Schistosoma mansoni* infection, 2017 study.**

881 Results of the multivariable analysis of risk factors for morbidity due to *Schistosoma*
882 *mansoni* infection among participants from 13 villages in Ituri province (n=586).
883 Only diagnostic results of the point-of-care circulating cathodic antigen (POC-CCA)
884 test have been considered.

885 **Table S5: Prevalence of periportal fibrosis (PPF) by age, sex, village, and *S. mansoni***

886 **infection status in the 2017 study.** Results from 13 purposively selected villages of
887 Ituri province (n=586). Prevalence with combined approach and Kato-Katz based
888 intensity.

889 **Table S6: Prevalence of hepatomegaly, splenomegaly and overall organomegaly by age,**

890 **sex, village, and *S. mansoni* infection status in the 2017 study.** Results from 13
891 purposively selected villages of Ituri province (n=586). Prevalence with combined
892 approach.

893 **Table S7: *S. mansoni* infection intensity by liver patterns in the 2017 study.** Study conducted

894 in 13 purposively selected villages in Ituri province (n=586). Only results of the Kato-
895 Katz test have been considered in this analysis.

896 **Table S8: Univariable analysis of risk of liver patterns and periportal fibrosis (PPF) by *S.***

897 ***mansoni* infection status with different diagnostic approaches in the 2017 study.**
898 Results from 13 purposively selected villages of Ituri province (n=586). Analysis with
899 Kato-Katz alone, POC-CCA alone, and with the combined approach of Kato-
900 Katz+POC-CCA.

901

902 **Figures**

903

904 **Figure S1:** Liver image patterns associated with schistosomiasis, by [21].